NEW ORLEANS and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo” or the…
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the…
Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination…
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a…
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V….
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled…
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced…
BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th…
PharmAla Biotech will provide MDMA to Revive Therapeutics in their development of an MDMA Microneedle…
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical…
TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:…
Company Files Investor Presentation and Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE…
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
$10M milestone payment triggered by advancement of clinical program in Japan. Multiple centers in the…
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca)…
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…
BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be…